Macrosalb

Macrosalb, the active ingredient in Macrosalb, is a radiopharmaceutical presented as a diagnostic kit for intravenous use. It is employed in nuclear medicine procedures to visualize organ function and detect disease in patients undergoing imaging studies.

GNH USA supplies Macrosalb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Macrosalb is used in nuclear medicine imaging to assess various organ systems and disease processes.

Bone Scan: enables detection of skeletal metastases and fractures. Myocardial Perfusion Imaging: assists in evaluating coronary artery disease and myocardial viability. Renal Scintigraphy: helps assess renal perfusion and function.

Macrosalb may cause transient reactions following injection.

Common Side Effects: - Injection site pain or erythema - Mild nausea or vomiting - Headache or dizziness - Transient flushing or warmth - Mild hypotension - Temporary allergic skin rash

Serious or Rare Side Effects: - Anaphylactic reaction - Severe hypotension or cardiovascular collapse - Radiation‑induced skin injury at injection site - Acute renal impairment in susceptible patients - Hematologic abnormalities such as leukopenia - Thyroid dysfunction due to radioactive iodine release

Prior to administration, clinicians should evaluate patient history and specific risk factors. - Pregnancy: avoid unless essential, as radiation may affect fetal development. - Breastfeeding: discontinue breastfeeding for an appropriate period after administration. - Renal impairment: consider reduced activity or alternative agents. - Known allergy to kit components: contraindicated. - Radiation safety: follow local regulations for handling and disposal of radioactive material. - Store at ambient temperature: keep in original packaging, protect from light and moisture.

Macrosalb may interact with drugs or substances that alter radiotracer distribution or radiation exposure.

Major Interactions (Avoid): - High‑dose iodine or iodinated contrast agents: can block thyroid uptake of technetium. - Certain chelating agents (e.g., dimercaprol): may interfere with radiolabeling efficiency.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may affect myocardial perfusion imaging results. - Diuretics: can modify renal tracer clearance. - Thyroid‑blocking agents (e.g., perchlorate): may alter thyroid imaging. - Anticoagulants: increase risk of bleeding at injection site. - Sedatives: may mask transient hypotensive reactions.